Medizinische Universität Graz - Research portal
Absenger Gudrun |
Presentations at scientific and public conferences
John, N; Terbuch, A; Konjic, S; Absenger, G; Jost, PJ; Lindenmann, J; Fediuk, M; Sassmann, T; Wurm, R; Zacharias, M; Posch, F; Hochmaier, MJ; Fabikan, H; Weinlinger, C; Illini, O; Horvath, L; Gamerith, G; Pircher, A; Brcic, L
Prognostic impact of targetable driver alterations in resected early-stage lung cancer
WIEN KLIN WOCHENSCHR. 2024; 136(S13):S531-S531.-48. Jahrestagung ÖGP - 8th Jahrestagung OGTC; SEP 26-28, 2024; Vienna, Austria.
[Poster]
Web of Science
Brcic, L; John, N; Schlintl, V; Zacharias, M; Kalson, L; Prein, K; Lax, SF; Lindenmann, J; Absenger, G; Terbuch, A
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
The 69th Autumn Anual Meeting of the Japanese Society of Pathology; NOV 09-10, 2023; Kurume, JAPAN. 2023.
[Poster]
He, K; Absenger, G; Pickering, C; Guerrier, C; Dhar, C; Xu, G; Hartness, J; Rice, R; Schwarz, F; Serie, D; Hommes, D; Brcic, L
Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
ANN ONCOL. 2023; 34: S724-S724.
Doi: 10.1016/j.annonc.2023.09.2330
[Poster]
Web of Science
FullText
FullText_MUG
Barth, D; Stradner, M; Hutterer, H; Spiegelberg, J; Bauernhofer, T; Absenger, G; Jost, P; Pichler, M
Blood-based B-cell subtypes as predictors of treatment response during treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2022. 2022; -OeGHO Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA.
[Poster]
Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A
Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557.
Doi: 10.1016/j.annonc.2022.10.344
[Poster]
Web of Science
FullText
FullText_MUG
Hochmair, M; Absenger, G; Ay, L; Robinson, I; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipou, A
Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients
J THORAC ONCOL. 2022; 17(9): S561-S561.
[Poster]
Web of Science
Hochmair, M; Schmidinger, M; Ay, L; Robinson, I; Absenger, G; Pichler, M; Nguyen, VA; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: multi-center Validation of a new microbiome-based Biomarker to predict Response to Cancer Immunotherapy
ONCOL RES TREAT. 2022; 45(SUPPL 2):229-229.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konji, S; Valipour, A
Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
WIEN KLIN WOCHENSCHR. 2022; 134(19-20):727-728.
Web of Science
Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Porubsky, Ch; Absenger, G; Mykoliuk, I; Brcic, L; Anegg, U; Maier, A; Jost, P; Smolle, J; Smolle-Juettner, FM
Recurrence and survival following surgery of T3 esophageal carcinoma with curative intent. Role of circumferential resection margin.
European Surgrey- ACA. 2022; 54: 50-50.-63. Österreichischer Chirurgenkongress; JUN 15-17, 2022; Graz, AUSTRIA.
[Oral Communication]
Mykoliuk, I; Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Porubsky, Ch; Terbuch, A; Absenger, G; Brcic, L; Anegg, U; Maier, A; Smolle, J; Smolle-Juettner, FM
Perioperative complications in esophagectomy for carcinoma are correlated to a higher recurrence rate.
European Surgery- ACA. 2022; 54: 67-68.-63. Österreichischer Chirurgenkongress; JUN 15-17, 2022; Graz, AUSTRIA.
[Oral Communication]
Okresa, L; Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Mykoliuk, I; Terbuch, A; Absenger, G; Roj, A; Anegg, U; Maier, A; Smolle, J; Smolle-Juettner, FM
Esophagectomy in octogenarians – a worthwhile indication?
European Surgery- ACA. 2022; 54: 124-124.-63. Österreichischer Chirurgenkongreß; JUN 15-17, 2022; Graz, AUSTRIA.
[Poster]
Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
Robinson, I; Hochmair, MJ; Jansen, C; Pacifico, C; Sladek, B; Knabl, A; Gasche, N; Absenger, G; Pichler, M; Valipour, A
Prediction of immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC) patients using a microbiome-based biomarker
WIEN KLIN WOCHENSCHR. 2022; 134(19-20): 742-742.
[Poster]
Web of Science
Robinson, I; Schmidinger, M; Hochmair, MJ; Ay, L; Absenger, G; Pichler, M; Nguyen, VAF; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
ANN ONCOL. 2022; 33(7):S592-S592.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); SEP 09-13, 2022; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2022.07.149
[Poster]
Web of Science
FullText
FullText_MUG
Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A
Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202.
[Poster]
Web of Science
Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A
Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229.
[Poster]
Web of Science
Terbuch, A; Absenger, G; Steinlechner, S; Mayer, M; Jost, P; Wurm, R; Wohlkönig, C; John, N; Olschewski, H; Richtig, E; Koch, L; Winder, T; Wöll, E; Gerger, A;
AUTRICHE – AUsTrian Registry for Immune CHEckpoint inhibitors
Jahrestagung der DGHO; OKT 1-4, 2021; Berlin. 2021.
[Poster]
Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Setinek, U; Krenbek, D; Prosch, H; Rauter, M; Schumacher, M; Woll, E; Wass, R; Brehm, E; Absenger, G; Bundalo, T; Errhalt, P; Urban, M; Valipour, A
Later-line treatment with lorlatinib in ALK-and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis.
WIEN KLIN WOCHENSCHR. 2020; 132(19-20):610-610.
[Poster]
Web of Science
Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.234
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108.
[Poster]
Web of Science
Dandachi, N; Absenger, G; Brcic, L; Kashofer, K; Terbuch, A; Jaritz, L; Stanzer, S; Balic, M
Feasibility and clinical value of serial circulating tumor DNA testing in metastatic lung adenocarcinoma patients undergoing TKI treatment
ONCOL RES TREAT. 2019; 42: 213-213.
[Poster]
Web of Science
Hochmair, MJ; Weinlinger, C; Fabikan, H; Illini, O; Krenbek, D; Setinek, U; Watzka, S; Koger, R; Meilinger, M; Absenger, G; Wanke, M; Semmelweis, C; Rauter, M; Valipour, A
Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
J THORAC ONCOL. 2019; 14(10):S847-S847.
Doi: 10.1016/j.jtho.2019.08.1831
[Poster]
Web of Science
FullText
FullText_MUG
Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A
Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115.
[Poster]
Web of Science
Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
Hochmair, M; Holzer, S; Filipits, M; Mohn-Staudner, A; Errhalt, P; Absenger, G; Bundalo, T; Arns, M; Setinek, U; Mikes, R; Kolb, R; Schumacher, M; Zochbauer-Muller, S; Patocka, K; Haslbauer, F; Rudzki, J; Burghuber, O
EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
J THORAC ONCOL. .. 2017; 12(1):S1254-S1254.
Doi: 10.1016/j.jtho.2016.11.1769
[Poster]
Web of Science
FullText
FullText_MUG
Hochmair, M; Holzer, S; Filipits, M; Mohn-Staudner, A; Arns, M;, Errhalt, P; Absenger, G; Koller-Herzog, U; Setinek, U; Haslbauer, F; Korger, MA; Patocka, K; Kolb, R; Burghuber, O
EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
J Clin Oncol 34, 2016 (suppl; abstr e20572). 2016; -ASCO Annual Meeting ; Jun 3 -7, 2016 ; Chicago, USA.
Holzer, S; Hochmair, M; Filipits, M; Mohn-Staudner, A; Errhalt, P; Absenger, G; Bundalo, T; Arns, BM; Setinek, U; Mikes, R; Kolb, R; Schumacher, M; Zochbauer-Muller, S; Patocka, K; Haslbauer, F; Rudzki, J; Burghuber, OC
EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
WIEN KLIN WOCHENSCHR. 2016; 128(19-20):769-770.
[Poster]
Web of Science
Szkandera, J; Gerger, A; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Friesenbichler, J; Stojakovic, T; Eberhard, K; Leithner, A; Pichler, M
The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas.
Abstractbook of EMSOS 2014, P02.04. 2014; 44--27th Annual Meeting of the European Musculo-Skeletal Oncology Society (EMSOS); May 22-23, 2014; Vienna, AUSTRIA.
[Poster]
Szkandera, J; Gerger, A; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Friesenbichler, J; Trajanoski, S; Stojakovic, T; Eberhard, K; Leithner, A; Pichler, M
The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas
Jahrestagung der DGHO, ÖGHO, SGMO und SGH ; OKT 10-14, 2014; Hamburg, Deutschland. 2014.
[Oral Communication]
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Kielhauser, S; Gerger, A; Absenger, G; Glehr, M; Szkandera, J; Samonigg, H; Krippl, P; Renner, W
Association of a common single nucleotide polymorphism in the TRAIL-R1 gene with relapse-free survival in rectal cancer patients.
Annals of Oncology. 2013; 24, Suppl. 4: iv51-iv52.-ESMO 15th World Congress on Gastrointestinal Cancer; JULY, 3-6, 2013; Barcelona, SPAIN. (ISBN: 0923-7534 )
[Poster]
Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Stotz, M; Zacherl, M; Renner, W; Leithner, A; Gerger, A
Common gene variants in RAD51, XRCC2 and XPD are not associated with clinical outcome in soft-tissue sarcoma patients.
Abstracts of 26th EMSOS; P4:102. 2013; -26th EMSOS; MAY 29-31, 2013; Gothenburg, SWEDEN.
[Poster]
Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Zacherl, M; Samonigg, H; Stojakovic, T; Gerger, A; Leithner, A
Elevated preoperative neutrophil/lymphocyte ratio is associated
with poor prognosis in soft-tissue sarcoma patients.
Abstracts of 26th EMSOS; PSR:110. 2013; -26th EMSOS; MAY 29-31, 2013; Gothenburg, SWEDEN.
[Oral Communication]
Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Zacherl, M; Samonigg; H; Stojakovic, T; Gerger, A; Leithner, A
Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients.
Abstracts of 26th EMSOS; P6:101. 2013; -26th EMSOS; MAY 29-31, 2013; Gothenburg, SWEDEN.
[Poster]
Szkandera, J; Absenger, G; Weissmueller, M; Pichler, M; Stotz, M; Lax, S; Leitner, G; Asslaber, M; Renner, W; Gerger, A
Prediction of clinical outcome in stage II and III colon cancer by a common gene variant in AXIN2
Journal of Clinical Oncology . 2013; 30(34):-2013 Gastrointestinal Cancers Symposium; Jan 24-26, 2013; San Francisco, USA.
[Poster]
Szkandera, J; Absenger, G; Weissmueller, M; Stotz, M; Pichler, M; Lax, S; Leitner, G; Asslaber, M; Renner, W; Gerger, A
A common gene variant in AXIN2 predicts clinical outcome in stage II and III colon cancer
387 (A55). 2013; -ASCO GI; JAN 24-26, 2013; San Francisco, USA.
[Poster]
Szkandera, J; Gerger, A; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Samonigg, H; Maurer-Ertl, W; Stojakovic, T; Ploner, F; Leithner, A; Pichler, M
VALIDATION OF THE PROGNOSTIC RELEVANCE OF PLASMA C-REACTIVE PROTEIN LEVELS IN SOFT TISSUE SARCOMA.
Abstracts of the 18th Annual Meeting CTOS, P 94. 2013; -Connective Tissue Oncology Society 18th Annual Meeting; OCT 30 - NOV 2, 2013; New York, USA.
[Poster]
Szkandera, J; Pichler, M; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Ploner, F; Stojakovic, T; Samonigg, H; Leithner, A; Gerger, A
THE ELEVATED PRE-OPERATIVE PLASMA FIBRINOGEN LEVEL IS AN INDEPENDENT NEGATIVE PROGNOSTIC FACTOR FOR CANCER-SPECIFIC; METASTASIS-FREE AND OVERALL SURVIVAL IN SOFT-TISSUE SARCOMA PATIENTS.
Abstracts of the 18th Annual Meeting CTOS, P 93. 2013; -Connective Tissue Oncology Society 18th Annual Meeting; OCT 30 - NOV 2, 2013; New York, USA.
[Poster]
Winder, T; Szkandera, J; Absenger, G; Weismüller, M; Pichler, M; Stotz, M; Lax, S; Leitner, G; Asslaber, M; Renner, W; Samonigg, H; Gerger, A
A functional germline variant in Hedgheog pathway gene GLI1 identifies patients at high risk of tumor recurrence in stage II and III colon cancer
http://worldgicancer.com/WCGI/WGIC2013/. 2013; -World Congress on Gastrointestinal Cancer; July 3-6, 2013; Barcelona, Spain.
[Oral Communication]
Absenger, G;
Orphan diseases in der Onkologie: Thymom
OeGHO Frühjahrstagung 2012 ; 12. April 2012 - 14. April 2012 ; Graz, Austria. 2012.
[Oral Communication]
Absenger, G; Szkandera, J; Weissmüller, M; Postlmayr, U; Pichler, M; Loibner, H; Samonigg, H; Gerger, A
The preoperative neutrophil to lymphocyte ratio predicts disease-free survival and overall survival in patients with stage II and III colon cancer
Onkologie - International Journal for Cancer Research and Treatment. 2012; 35(6):55-56.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaft für Hämatologie und Onkologie; OCT 19-23, 2012; Stuttgard, Germany.
[Poster]
Absenger, G; Szkandera, J; Weissmuller, M; Postlmayr, U; Pichler, M; Loibner, H; Samonigg, HS; Gerger, A;
The preoperative neutrophil to lymphocyte ratio predicts disease-free survival and overall survival in patients with stage II and III colon cancer.
ONKOLOGIE. ONKOLOGIE35: 55-56. BASEL: KARGER;
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Absenger, G; Szkandera, J; Samonigg, H; Krippl, P; Renner, W;
COMMON VEGF GENE POLYMORPHISMS ARE NOT ASSOCIATED WITH RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS.
ANN ONCOL. 2012; 23: 86-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Thurner, E-M; Absenger, G; Szkandera, J; Samonigg, H; Glehr, M; Krippl, P; Renner, W
Genetic variants of UGT1A4 and their impact on relapse-free survival in Tamoxifen treated breast cancer patients.
Onkologie. 2012; 35(S 6):64-64.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
Krenn-Pilko, S; Thurner, EM; Absenger, G; Renner, W; Gerger, A; Kapp, KS; Langsenlehner, U; Langsenlehner, T;
Association Between Variants in the VEGF Gene and Distant Metastases in Postmenopausal Breast Cancer Patients.
EUR J CANCER. EUROPEAN JOURNAL OF CANCER48: S271-S271. OXFORD: ELSEVIER SCI LTD; ( Presented at: 22nd Biennial Congress of the European-Association-for-Cancer-Research, Barcelona, SPAIN, JUL 07-10, 2012)
Doi: 10.1016/S0959-8049(12)71726-4
[Poster]
Web of Science
FullText
FullText_MUG
Krenn-Pilko, S; Thurner, EM; Renner, W; Absenger, G; Gerger, A; Kapp, KS; Langsenlehner, T; Langsenlehner, U
The Development of Distant Metastases in Postmenopausal Woman with Breast Cancer in Association with VEGF Gene Polymorphisms
EUR J CANCER. 2012; 48: 63-63.-24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; NOV 06-09, 2012; Dublin, IRELAND.
Doi: 10.1016/S0959-8049(12)72008-7
[Poster]
Web of Science
FullText
FullText_MUG
Marx-Neuhold, EA; Zulus, B; Absenger, G; Szkandera, J; Schippinger, W; Gerger, A; Renner, W
A common polymorphism in the promoter of the erythropoietin gene is associated with delayed onset of peripheral arterial disease.
Drug Metabolism and Drug Interactions. 2012; 27(3):39-39.-6th Santorini Conference Biologie Prospective; SEP 30-OKT 2, 2012; Thira, GREECE.
[Poster]
Szkandera, J; Absenger, G; Dandachi, N; Regitnig, P; Lax, S; Stotz, M; Winder, T; Samonigg, H; Renner, W; Gerger, A
Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
WIEN KLIN WOCHENSCHR. 2012; 124(15-16):575-575.
[Poster]
Web of Science
Szkandera, J; Absenger, G; Stotz, M; Weissmuller, M; Winder, T; Langsenlehner, T; Samonigg, H; Renner, W; Schippinger, W; Gerger, A
The functional polymorphism of erythropoietin gene rs1617640 G > T is not associated with susceptibility and clinical outcome of early-stage breast cancer
WIEN KLIN WOCHENSCHR. 2012; 124(15-16):575-575.
[Poster]
Web of Science
Szkandera, J; Winder, T; Absenger, G; Stotz, M; Weissmuller, M; Langsenlehner, T; Hofmann, G; Samonigg, H; Renner, W; Gerger, A;
A COMMON GENE VARIANT IN PLS3 PREDICTS COLON CANCER RECURRENCE IN WOMEN.
ANN ONCOL. 2012; 23: 83-83.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Szkandera, J; Zulus, B; Absenger, G; Stotz, M; Weissmueller, M; Winder, T; Langsenlehner, T; Samonigg, H; Renner, W; Schippinger, W; Gerger, A
The functional rs1617640 polymorphism in the promoter of the erythropoietin gene is not associated with susceptibility and outcome of early-stage breast cancer.
Drug Metabolism and Drug Interactions. 2012; 27(3):22-22.-6th Santorini Conference Biologie Prospective.; SEP 30-OKT 2, 2012; Thira, GREECE.
[Poster]
Thurner, EM; Krenn-Pilko, S; Absenger, G; Hofmann, G; Gerger, A; Langsenlehner, U; Kapp, KS; Langsenlehner, T
Correlations between variants in the ERCC2 gene and the risk of the development of radiation induced late toxicity in prostate cancer patients
Onkologie - International Journal for Cancer Research and Treatment. 2012; 35(6):182-182.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaft für Hämatologie und Onkologie; OKT 19-23, 2012; Stuttgart, GERMANY. (ISBN: 978-3-318-02304-6 )
[Oral Communication]
Web of Science
Gerger, A; Zhang, W; Yang, D; Bohanes, PO; Ning, Y; Winder, T; Labonte, MJ; Wilson, PM; Benhaim, L; El-Khoueiry, R; Absenger, G; El-Khoueiry, AB; Iqbal, S; Lenz, H
Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy.
J Clin Oncol 29: 2011 (suppl; abstr 3592)2011; -2011 ASCO Annual Meeting; Jun 3-7, 2011; Chicago.
[Poster]
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Bitsche, S; Absenger, G; Samonigg, H; Krippl, P; Renner, W
RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS IS NOT ASSOCIATED WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN INTEGRIN RECEPTOR SUBUNITS
ANN ONCOL. 2011; 22: v109-v109.-ESMO 13th World Congress on Gastrointestinal Cancer ; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
A COMMON HEREDITARY SINGLE NUCLEOTIDE POLYMORPHISM IN THE IN THE GENE OF DEATH RECEPTOR 4 (TNFRSF10A) AND ITS IMPACT ON OVERALL SURVIVAL IN RECTAL CANCER PATIENTS
ANN ONCOL. . 2011; 22: v129-v129.-ESMO 13th World Congress on Gastrointestinal Cancer; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
Common single nucleotide polymorphisms in the genes of integrin alpha-2 and beta-3 subunits are not associated with overall survival in rectal cancer patients
ONKOLOGIE. 2011; 34: 245-246.-Gemeinsame Jahrestagung 2011 der DGHO, ÖGHO, SGMO und SGH+SSH; SEP 30-OCT 4, 2011; Basel, SWITZERLAND.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Samonigg, H; Krippl, P; Renner, W
COMMON VEGF RECEPTOR GENE POLYMORPHISMS AND THEIR INFLUENCE ON OVERALL SURVIVAL IN COLORECTAL CANCER PATIENTS
Annals of Oncology2010; 21(S 6):35-35.-12th World Congress on Gastrointestinal Cancer; June 30-July 3, 2010; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Samonigg, H; Krippl, P; Renner, W
ASSOCIATION OF COMMON SINGLE NUCLEOTIDE POLYMORPHISMS IN INTEGRINS WITH METASTASIS-FREE SURVIVAL IN RECTAL CANCER PATIENTS
Annals of Oncology2010; 21(S 6):59-59.-12th World Congress on Gastrointestinal Cancer; June 30-July 3, 2010; Barcelona, SPAIN.
[Poster]
Web of Science
Knechtel, G; Szkandera, J; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Samonigg, H; Renner, W; Dehchamani, D; Gerger, A
Single nucleotide polymorphisms in the hypoxia-inducible factor 1 gene and colorectal cancer risk
Onkologie-International Journal for Cancer Research and Treatment2010; 33(S6):225-226.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OKT 1-5, 2010; Berlin, GERMANY. (ISBN: 978-3-8055-9633-6 )
[Oral Communication]
Web of Science
Knechtel, G; 1, Szkandera, J; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Samonigg, H; Renner, W; Langner, C; Dehchamani, D; Gerger, A;
Single nucleotide polymorphisms in the hypoxia-inducible factor 1 gene and colorectal cancer risk
MEMO Suppl 01/10; 2010; 16-17.-Frühjahrstagung 2010 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 8-10, 2010; Bregenz, AUSTRIA.
[Poster]
Szkandera, J; Knechtel, G; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Langsenlehner, T; Dehchamani, D; Samonigg, H; Renner, W; Gerger, A
Association of Hypoxia Inducible Factor 1-alpha Gene Polymorphisms and Colorectal Cancer Prognosis.
Onkologie-International Journal for Cancer Research and Treatment2010; 33(S6):226-226.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OKT 1-5, 2010; Berlin, GERMANY. (ISBN: 978-3-8055-9633-6 )
[Oral Communication]
Web of Science
Szkandera, J; Knechtel, G; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Langsenlehner, T; Dehchamani, D; Samonigg, H; Renner, W; Gerger, A
Assiciation of hypoxia inducible factor 1-alpha gene polymorphisms and colorectal cancer prognosis.
MEMO Suppl 01/10; 2010; 16-16.-Frühjahrstagung 2010 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 8-10, 2010; Bregenz, AUSTRIA.
[Poster]
Szkandera, J; Ploner, F; Bauernhofer, T; Kasparek, AK; Payer, F; Balic, M; Knechtel, G; Gerger, A; Galle; Samonigg, H; Hofmann, g;
Paraneoplastic limbic encephalitis in a patient with extragonadal chorioncarcinoma - the significance of onconeural antibodies: a case report
MEMO Suppl 01/10; 2010; 20-21.-Frühjahrstagung 2010 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 8-10; Bregenz, AUSTRIA .
[Poster]
Gerger, A; Renner, W; Langsenlehner, T; Hofmann, G; Knechtel, G; Szkandera, J; Samonigg, H; Krippl, P; Langselnlehner, U
Association of Interleukin-10 gene variation wit breast cancer prognosis
Frühjahrstagung 2009 der Österreichischen Gesellschaft für Hämatologie und Onkologie; April 14-16, 2009; Salzburg. 2009.
[Poster]
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Szkandera, J; Krippl, P; Renner, W
The 683A>C polymorphism in the ligand binding domain of TRAILR-1 (TNFRSF10A) is not associated with colorectal cancer survival.
Annals of Oncology2009; 20(S 7):31-31.-11th World Congress on Gastrointestinal Cancer ; JUNE 24-27, 2009; Barcelona, SPAIN.
[Poster]
Web of Science
Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Szkandera, J; Krippl, P; Renner, W
Colorectal cancer survival and its association to a common hereditary polymorphism in the gene of Death Receptor 4 (TNFRSF10A)
MEMO Suppl 02/09; 2009; 2: 21-21.-Frühjahrstagung 2009 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APRIL 16-18, 2009; Salzburg, AUSTRIA.
[Poster]
Knechtel, G; Gerger, A; Renner, W; Langsenlehner, T; Hofmann, G; Szkandera, J; Samonigg, H; Krippl, P; Langsenlehner, U
Analysis of common germline polymorphisms to predict metastasis in node-positive breast cancer
MEMO Suppl 02/09; 2009; 2: 20-21.-Frühjahrstagung 2009 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APRIL 16-18, 2009; Salzburg, AUSTRIA.
[Oral Communication]
Knechtel, G; Stoeger, H; Szkandera, J; Dorr, K; Beham, A; Samonigg, H
Desmoid tumor treated with polychemotherapy followed by Imatinib
A case report and a review of literature
MEMO Suppl 02/09; 2009; 2: 20-20.-Frühjahrstagung 2009 der Österreichischen Gesellschaft für Hämatologie und Onkologie ; APRIL 14-16, 2009; Salzburg, AUSTRIA.
[Poster]